Takeda breaks off five-year pact with microbiome partner, handing back two preclinical drugs
When Takeda first partnered up with Finch Therapeutics in 2017, the Japanese pharma put on the map what was still a very early-stage microbiome player aiming to capitalize on the idea that you could reap the benefits of fecal transplants with an oral pill — and its preclinical program for inflammatory bowel disease.
Over the next few years, Takeda rejigged the alliance a few times, getting its hands on a second drug, taking more responsibility for development and manufacturing, and later tapping Finch to conduct more feasibility work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.